Kenvue wins FDA nod for first OTC acetaminophen-naproxen combo

The US Food and Drug Administration approved Kenvue's over-the-counter fixed-dose combination pill that pairs acetaminophen with naproxen sodium, the company said. The product contains 325 mg of acetaminophen and 110 mg of naproxen sodium, with pain relief lasting up to 12 hours. It is the first OTC drug to combine the two active ingredients.

Kenvue (KVUE) markets Tylenol (acetaminophen) and already has a strong presence in the pain relief category. The new combination could broaden its OTC portfolio and compete with single-ingredient products.

Kenvue's Alpha Score stands at 51 out of 100, labeled Mixed, reflecting neutral quantitative sentiment. The KVUE stock page is available for further analysis.